company
as of 2026-07-01LB Pharmaceuticals Inc.
LBRX
CIK 0001691082ticker LBRX
at a glance
Cash $320.7M (as of 2026-03-31)
5 trials sponsored · 1 assets in the graph
Synthesized from structured facts only — each point cited above.
Financials
SEC EDGAR XBRL · latest period per metric
Cash$320.7M2026-03-31
Ga Expense$7.5M2026-03-31
Net Income Loss-$19.1M2026-03-31
Rnd Expense$14.6M2026-03-31
Stockholders Equity$378.7M2026-03-31
Total Assets$393.5M2026-03-31
Pipeline
1 assets
Recent filings
SEC EDGAR
Facts & assertions
11 sourced
Financial Status
pre-revenue / loss-making
Guided Cash Position Q1 2026Cash, cash equivalents + marketable securities as of 2026-03-31 per Q1'26 update ($365.6M). Note: exceeds the $320.7M bare-cash figure from SEC XBRL (Source 4) because it includes marketable securities/investments.
365,600,000
Guided Cash RunwayCompany guidance (Q1'26): $365.6M cash funds operations into Q2 2029 — through NOVA-2, ILLUMINATE-1, and MDD readouts. Note this DIFFERS from our mechanical ~49mo runway estimate (Source 4); the company figure accounts for accelerating trial burn.
into Q2 2029
Implied Monthly Burn
6,508,333
Implied Runway Months
49.3
Latest Cash
320,676,000
Latest Ga Expense
7,459,000
Latest Net Income Loss
-19,054,000
Latest Rnd Expense
14,645,000
Latest Stockholders Equity
378,693,000
Latest Total Assets
393,482,000
relationships
The graph out of here
asset
LB-102
drugsmall molecule